Orlandi Demo ML, Holthausen Nunes D, Mendes Marcon CE
Issues - Dicembre 2022
Orlandi Demo ML, Holthausen Nunes D, Mendes Marcon CE
Alpalhão M, Duarte J, Diogo R, et al.
Lower limbs are the most difficult-to-treat body region of patients with psoriasis: pooled analysis of CLEAR and CLARITY studies of secukinumab versus ustekinumab by body region
BioDrugs 2022;36_781-789Narang T, Bhandari A, Mehta H, et al.
Effect of lockdown due to COVID-19 on health and lifestyle of psoriasis patients: a web-based survey
Indian Dermatol Online J. 2022 Sep-Oct; 13(5): 625-628Wang YC, Lin YH, Ma SH, et al.
Infection risk in psoriatic patients receiving tumour necrosis factor inhibitors: a 20-year systematic review and meta-analysis of randomized controlled trials
J Eur Acad Dermatol Venereol. 2022 Dec;36(12):2301-2315Reich K, Kristensen LE, Smith SD, et al.
Efficacy and safety of ixekizumab versus adalimumab in biologic-naïve patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial
Dermatol Pract Concept. 2022 Apr 1;12(2):e2022104Coates LC, Mease P, Kronbergs A, et al.
Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
Clin Rheumatol. 2022 Oct;41(10):3035-3047Malagoli P, Dapavo P, Pavia G, et al.
Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis)
Dermatol Ther. 2022 Aug;35(8):e15608Gönülal M, Altunay İK, Doğan S, et al.
Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience
Dermatol Ther. 2022 Oct 22;e15955Coyne M, Rinaldi A, Brigham K, et al.
Impact of routines and rituals on burden of treatment, patient training, cognitive load, and anxiety in self-injected biologic therapy
Patient Prefer Adherence. 2022 Sep 19;16:2593-2607Jaworecka K, Rzepko M, Marek-Józefowicz L, et al.
The impact of pruritus on the quality of life and sleep disturbances in patients suffering from different clinical variants of psoriasis
J Clin Med. 2022 Sep 22;11(19):5553Chicharro P, Llamas-Velasco M, Armesto S, et al.
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: multicenter study in 384 Spanish patients
Dermatol Ther. 2022 Oct 12;e15929Rathod A, Neema S, Radhakrishnan S, et al.
Palmoplantar plaque psoriasis is associated with diabetes, hypertension, obesity, and metabolic syndrome-a case-control study
Indian Dermatol Online J. 2022 Sep 5;13(5):606-610Mrowietz U, Barker J, Conrad C, et al.